Brolamfetamine hydrobromide, (R)- | 53581-79-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Brolamfetamine hydrobromide, (R)-
• 英文别名: (2R)-1-(4-bromo-2,5-dimethoxyphenyl)propan-2-amine;hydrobromide
• CAS: 53581-79-6
• 化学式: C11H17Br2NO2
• 分子量: 355.07
• InChiKey: KOUBEZAODVTFTG-OGFXRTJISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.93
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  44.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Agonism of the 5HT2A receptor for treatment of thermoregulatory dysfunction
  申请人：Wyeth

  公开号：US20040063721A1

  公开（公告）日：2004-04-01

  The present invention relates to a method for treating thermoregulatory disorders by administering compounds and compositions of compounds which by modulating 5HT levels activate the 5HT 2a receptor. The invention also relates to therapy using 5HT 1a antagonists and SRIs in combination and pharmaceutical compositions and products containing it. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.

  本发明涉及一种通过施用化合物和化合物组合物治疗体温调节失调的方法，这些化合物和化合物组合物通过调节 5HT 水平激活 5HT 2a 受体。本发明还涉及使用 5HT 1a 拮抗剂和 SRIs 结合使用的治疗方法，以及含有这种药物的药物组合物和产品。需要强调的是，提供本摘要是为了符合要求摘要能使检索者或其他读者迅速确定技术公开主题的规则。提交本摘要的前提是，本摘要不用于解释或限制权利要求的范围或含义。
• AGONISM OF THE 5HT 2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION
  申请人：Wyeth

  公开号：EP1534258A2

  公开（公告）日：2005-06-01
• [EN] AGONISM OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION<br/>[FR] AGONISME DU RECEPTEUR 5HT2A POUR LE TRAITEMENT DU DYSFONCTIONNEMENT DE LA THERMOREGULATION
  申请人：WYETH CORP

  公开号：WO2004016256A2

  公开（公告）日：2004-02-26

  The present invention relates to a method for treating thermoregulatory disorders by administering compounds and compositions of compounds which by modulating 5HT levels activate the 5HT2a receptor. The invention also relates to therapy using 5HT1a antagonists and SRIs in combination and pharmaceutical compositions and products containing it.